...
首页> 外文期刊>Cancer radiotherapie: journal de la Soci閠?fran鏰ise de radiotherapie oncologique >Adjuvant chemotherapy followed by conformal chemoradiotherapy in gastric carcinoma
【24h】

Adjuvant chemotherapy followed by conformal chemoradiotherapy in gastric carcinoma

机译:胃癌的辅助化疗及随后的适形放化疗

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose. - Analysis of the feasibility and results of adjuvant chemotherapy followed by conformal chemoradiotherapy after surgery for gastric carcinoma. Patients and methods. - Twenty-six patients (R0 or Rl) were treated postoperatively by three cycles of 5-fluorouracil (5-FU) and cisplatin, followed by a concomitant association of LV5FU2 chemotherapy with a conformal radiotherapy of 45 Gy. Results. - The tumor was classified pT3-T4 in 77% of the patients and 92.5% had a nodal involvement (pNl: 54%; pN2: 31%).Feasibility. - (1) Adjuvant chemotherapy: nausea/vomiting grade Will: 12 patients (48%); neutropenia grade Ill/TV: two patients; completed in all patients, except one. (2) Chemoradiotherapy: nausea/vomiting grade MIL 10 patients; diarrhea grade II/3: two patients; oesophagitis grade MIL two patients; myocardial infarction/pulmonary embolism: two patients. All patients except one received the planned dose of 45 Gy. Radiotherapy was interrupted in six cases, with a median duration of 14 days. Survival: with a median follow-up of 30 months, 65% of the patients were alive without disease; median survival was 32 months. Conclusion. - This postoperative schedule was judged feasible. It allowed the deliverance of a more intensified chemotherapy than the classical schedule. Its clinical benefit must be evaluated in a phase III trial.
机译:目的。 -分析胃癌术后辅助化疗后再进行保形放化疗的可行性和结果。患者和方法。 -对26例患者(R0或R1)进行了3个周期的5-氟尿嘧啶(5-FU)和顺铂治疗,并随后进行了LV5FU2化疗和45 Gy适形放疗的联合治疗。结果。 -在77%的患者中肿瘤被归类为pT3-T4,有92.5%的淋巴结受累(pN1:54%; pN2:31%)。 -(1)辅助化疗:恶心/呕吐等级为:12例(48%);中性粒细胞减少症等级I / TV:两名患者;除一名患者外,所有患者均已完成。 (2)放化疗:恶心/呕吐等级MIL 10例;腹泻等级II / 3:两名患者;食管炎为MIL级2例;心肌梗塞/肺栓塞:两名患者。除一名患者外,所有患者均接受了45 Gy的计划剂量。放疗中断了6例,中位持续时间为14天。生存:平均随访30个月,有65%的患者还活着,没有疾病;中位生存期为32个月。结论。 -该术后时间表被认为是可行的。与传统的治疗方案相比,它可以使化疗的强度更高。必须在III期临床试验中评估其临床益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号